Drug Trial Radar · NCT00082433
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,221
Actual
Start
Nov 2003
Primary completion
Mar 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.
Conditions
- Cancer
- Breast Cancer
Interventions
Ixabepilone + CapecitabineDrug
Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
CapecitabineDrug
Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: from date of randomization until death
Locations
186 sites in 29 countries. Site status is shown where the registry gives one.
Local Institution
Tucson, Arizona
Local Institution
Beverly Hills, California
Local Institution
Corona, California
Local Institution
Hartford, Connecticut
Local Institution
Plantation, Florida
Local Institution
Boise, Idaho
Local Institution
Evanston, Illinois
Local Institution
Iowa City, Iowa
Local Institution
Louisville, Kentucky
Local Institution
Baton Rouge, Louisiana
Local Institution
Bethesda, Maryland
Local Institution
Boston, Massachusetts
Local Institution
Jackson, Mississippi
Local Institution
Columbia, Missouri
Local Institution
Voorhees Township, New Jersey
Local Institution
Albuquerque, New Mexico
Local Institution
Latham, New York
Local Institution
Mineola, New York
Local Institution
New York, New York
Local Institution
The Bronx, New York
Local Institution
Durham, North Carolina
Local Institution
Goldsboro, North Carolina
Local Institution
Hickory, North Carolina
Local Institution
Kinston, North Carolina
Local Institution
Canton, Ohio
Local Institution
Columbus, Ohio
Local Institution
Langhorne, Pennsylvania
Local Institution
Knoxville, Tennessee
Local Institution
Memphis, Tennessee
Local Institution
Dallas, Texas
Local Institution
Charlottesville, Virginia
Local Institution
Norfolk, Virginia
Local Institution
Richmond, Virginia
Local Institution
Marshfield, Wisconsin
Local Institution
Buenos Aires, Argentina
Local Institution
Mendoza, Argentina
Local Institution
Salta, Argentina
Local Institution
Santa Fe, Argentina
Local Institution
Avellaneda, Buenos Aires, Argentina
Local Institution
Bahía Blanca, Buenos Aires, Argentina
Showing 40 of 186 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.